Full metadata record
DC FieldValueLanguage
dc.creatorLópez-González, N. (Natalia)-
dc.creatorQuiroga-Varela, A. (Ana)-
dc.creatorGarbayo, E. (Elisa)-
dc.creatorCarballo-Carbajal, I. (Iria)-
dc.creatorFernández-Santiago, R. (Ruben)-
dc.creatorMonje, M.H.G. (Mariana H. G.)-
dc.creatorTrigo-Damas, I. (Inés)-
dc.creatorBlanco-Prieto, M.J. (María José)-
dc.creatorBlesa, J. (Javier)-
dc.date.accessioned2023-02-09T09:00:50Z-
dc.date.available2023-02-09T09:00:50Z-
dc.date.issued2018-
dc.identifier.citationLópez-González, N. (Natalia); Quiroga-Varela, A. (Ana); Garbayo, E. (Elisa); et al. "Advances in parkinson's disease: 200 years later". Frontiers in neuroanatomy. 12 (113), 2018,es_ES
dc.identifier.issn1662-5129-
dc.identifier.urihttps://hdl.handle.net/10171/65386-
dc.description.abstractWhen James Parkinson described the classical symptoms of the disease he could hardly foresee the evolution of our understanding over the next two hundred years. Nowadays, Parkinson's disease is considered a complex multifactorial disease in which genetic factors, either causative or susceptibility variants, unknown environmental cues, and the potential interaction of both could ultimately trigger the pathology. Noteworthy advances have been made in different fields from the clinical phenotype to the decoding of some potential neuropathological features, among which are the fields of genetics, drug discovery or biomaterials for drug delivery, which, though recent in origin, have evolved swiftly to become the basis of research into the disease today. In this review, we highlight some of the key advances in the field over the past two centuries and discuss the current challenges focusing on exciting new research developments likely to come in the next few years. Also, the importance of pre-motor symptoms and early diagnosis in the search for more effective therapeutic options is discussed.es_ES
dc.description.sponsorshipThe authors NDR, IT-D, and JB are currently funded by grant S2017/BMD-3700 (NEUROMETAB-CM) from Comunidad de Madrid co-financed with the Structural Funds of the European Union, Fundación BBVA and Fundación Tatiana Pérez de Guzmán el Bueno; RF-S was supported by a Jóvenes Investigadores grant (#SAF2015-73508-JIN) through the Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad (Plan Estatal de I+D+I 2013–2016) of the Spanish Ministry of Economy and Competitiveness (MINECO), and the Agencia Estatal de Investigación (AEI), which is cofunded by FEDER (AEI/FEDER/UE).es_ES
dc.language.isoenges_ES
dc.publisherFrontierses_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectParkinson’s diseasees_ES
dc.subjectGeneticses_ES
dc.subjectDrug delivery systemses_ES
dc.subjectNon-motor symptomses_ES
dc.subjectFocused ultrasoundes_ES
dc.titleAdvances in parkinson's disease: 200 years lateres_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.noteThis is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.es_ES
dc.identifier.doi10.3389/fnana.2018.00113-
dadun.citation.number113es_ES
dadun.citation.publicationNameFrontiers in neuroanatomyes_ES
dadun.citation.volume12es_ES
dc.identifier.pmid30618654-

Files in This Item:
Thumbnail
File
fnana-12-00113.pdf
Description
Size
1.2 MB
Format
Adobe PDF


Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.